Medical device maker Integra LifeSciences Holdings Corportion  (IART)is showcasing its Endoscopic Gastroc Release System (EGR) product line at the Annual Meeting of the American College of Foot and Ankle Surgeons (ACFAS) being held in Florida from 9th to 12th March.

The EGR system is used in surgical procedures for the treatment of ankle deformities like posterior heel cord or equinus contracture. This system is marketed by Integra’s Extremity Reconstruction sales organization.

Based on a study conducted by Integra, it was found that the EGR system and its gastrocnemius recession can be helpful in other surgical treatments like posterior tibial tendon dysfunction (PTTD), diabetic forefoot ulcers, symptomatic acquired flatfoot, and hallux valgus which affect ten of thousands of patients annually. Hence, the market has a huge potential for Integra.

Integra develops and markets surgical implants and medical instruments for orthopedics (burn, plastic and reconstructive surgery), neurosurgery (including neurotrauma), extremity reconstruction and general surgery in the U.S., Europe and the Asia Pacific to treat millions of patients every year. The company witnessed balanced growth during the last reported quarter in its two major segments, Orthopedic (up 8.1% year over year) and Neurosurgery (up 8.8% year over year). However this strong sales performance has been partially offset by the decline in revenue in Instruments (down 2.1% year over year).

In a drive to improve its business, presently Integra is investing in new product development and expansion of sales distribution. During the last quarter, the company reported a 12.9% rise in research and development cost and an 8% hike in selling, general and administrative expenses.

The company, however, faces direct competition in the Medical Instruments & Supplies industry from major players like Medtronic (MDT) and Stryker Corp. (SYK).

 
INTEGRA LIFESCI (IART): Free Stock Analysis Report
 
MEDTRONIC (MDT): Free Stock Analysis Report
 
STRYKER CORP (SYK): Free Stock Analysis Report
 
Zacks Investment Research